Alpha Tau Medical’s (DRTS) “Buy” Rating Reiterated at HC Wainwright

Posted by George Bondi on Jul 19th, 2026

HC Wainwright restated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS – Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $15.00 price target on the stock.

A number of other equities analysts have also recently issued reports on DRTS. Barclays increased their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Piper Sandler boosted their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 1st. Finally, LADENBURG THALM/SH SH raised their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $12.60.

Get Our Latest Report on Alpha Tau Medical

Alpha Tau Medical Trading Up 14.1%

DRTS opened at $13.55 on Thursday. Alpha Tau Medical has a twelve month low of $2.87 and a twelve month high of $14.11. The company has a fifty day moving average of $10.83 and a 200-day moving average of $8.42. The stock has a market cap of $1.22 billion, a PE ratio of -20.22 and a beta of 1.17. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last released its earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, sell-side analysts predict that Alpha Tau Medical will post -0.67 EPS for the current year.

Insider Buying and Selling

In other news, CFO Raphi Levy sold 2,270 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00. Following the completion of the sale, the chief financial officer owned 90,180 shares in the company, valued at $1,262,520. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 112,270 shares of company stock valued at $1,270,923 over the last ninety days. Company insiders own 39.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mariner LLC grew its holdings in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after buying an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC purchased a new stake in shares of Alpha Tau Medical during the fourth quarter valued at approximately $48,000. Everhart Financial Group Inc. bought a new stake in Alpha Tau Medical during the second quarter worth $126,000. Envestnet Asset Management Inc. purchased a new position in Alpha Tau Medical in the third quarter worth $62,000. Finally, Wells Fargo & Company MN boosted its position in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.